课题基金 / 基金详情

项目摘要

项目成果

DAVID W GOLDE的其他基金

相似基金

相关文献

中文摘要
翻译
血液肿瘤学项目的总体目标是开发和测试 治疗血液肿瘤的新的有效策略, 剂量密集的方法和生物疗法。 具体目标是: 1.为了测试治疗非霍奇金淋巴瘤的新剂量密集策略, 淋巴瘤和骨髓瘤伴生长因子和干细胞支持,和 监测微小残留病(项目2-1、2-2、2-3)。 2.开发和测试慢性淋巴细胞性白血病的治愈性治疗, 白血病与微小残留病评估(项目2-3)。 3.为血液肿瘤开发新的生物疗法(项目2- 7)。 项目2-1的重点是克隆型PCR的开发和应用 用于监测微小残留病,项目2-2检查了 干细胞动员治疗复发性淋巴瘤的剂量密集方法。 项目2-3提出了一种治疗慢性淋巴细胞性白血病的治疗方案。 白血病微小残留病PCR检测 项目2-4 探讨了低风险急性髓细胞白血病的治疗方法 联合化疗与集落刺激因子 治疗 项目2-5研究新的化疗和分化 血液肿瘤学中的药物。 这些项目遵循总的主题 与实体肿瘤紧密结合 肿瘤学项目。
英文摘要
The overall aim of the Hematologic Oncology Project is to develop and test new and effective strategies for treating hematologic neoplasms using dose-intense approaches and biologic therapies. The Specific Aims are: 1. To test novel dose-intense strategies for treating non-Hodgkin's lymphoma and myeloma with growth factor and stem cell support, and monitoring of minimal residual disease (Projects 2-1, 2-2, 2-3). 2. To develop and test a curative intent treatment for chronic lymphocytic leukemia with assessment of minimal residual disease (Project 2-3). 3. To develop new biologic therapies for hematologic neoplasia (Project 2- 7). Project 2-1 focuses on the development and application of a clonotypic PCR for monitoring of minimal residual disease and Project 2-2 examines a dose-intense approach to relapsed lymphoma with stem cell mobilization. Project 2-3 proposes a curative intent protocol for chronic lymphocytic leukemia with PCR determination of minimal residual disease. Project 2-4 examines a therapeutic approach to poor-risk acute myelogenous leukemia integrating chemotherapy concomitant with colony-stimulating factor treatment. Project 2-5 examines new chemotherapeutic and differentiating agents in hematologic oncology. These projects follow the overall themes of the Program Project grant and integrate closely with the Solid Tumor Oncology Program.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CORE--CLINICAL PROTOCOL SCIENTIFIC REVIEW AND MONITORING SYSTEM
CLINICAL RESEARCH
CLINICAL RESEARCH
CORE--CLINICAL PROTOCOL SCIENTIFIC REVIEW AND MONITORING SYSTEM
海外基金